List of Excipients in Branded Drug LAZANDA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Archimedes Pharma US Inc	LAZANDA	fentanyl citrate	51772-311	MANNITOL
Archimedes Pharma US Inc	LAZANDA	fentanyl citrate	51772-311	PECTIN
Archimedes Pharma US Inc	LAZANDA	fentanyl citrate	51772-311	PHENYLETHYL ALCOHOL
Archimedes Pharma US Inc	LAZANDA	fentanyl citrate	51772-311	PROPYLPARABEN
Archimedes Pharma US Inc	LAZANDA	fentanyl citrate	51772-311	SUCROSE
Archimedes Pharma US Inc	LAZANDA	fentanyl citrate	51772-311	WATER

LAZANDA Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

LAZANDA is a fentanyl citrate nasal spray built around a pectin-based mucoadhesive delivery system. Its commercial value lies less in the active ingredient, which is widely available, than in the combination of pectin gelation, dose-metering technology, nasal deposition, low-dose uniformity, and regulatory controls for transmucosal immediate-release fentanyl.

The main commercial opportunities are generic or 505(b)(2) versions with equivalent nasal performance, improved device economics, alternative mucoadhesive systems, and adjacent intranasal products using the same excipient and delivery platform. The main barriers are fentanyl regulatory controls, device-excipient integration, dose-content uniformity, human-factors validation, and patent claims directed to pectin-based nasal delivery.

What is LAZANDA and how does its formulation work?

LAZANDA contains fentanyl citrate and is approved as a metered-dose nasal spray for breakthrough cancer pain in opioid-tolerant adults. The product is available in 100 mcg and 400 mcg strengths per spray. Each bottle delivers eight sprays after priming, according to the FDA prescribing information.[1]

The formulation uses pectin to create a temporary gel after contact with nasal mucosa. This mechanism is intended to limit runoff into the nasopharynx and improve retention at the administration site. Fentanyl is then absorbed through the nasal mucosa, producing rapid systemic exposure.

LAZANDA formulation profile

Component	Function in the product	Commercial relevance
Fentanyl citrate	Active pharmaceutical ingredient	Highly potent opioid requiring strict containment and dose control
Pectin	Mucoadhesive and in situ gelling excipient	Core differentiation from conventional aqueous nasal sprays
Mannitol	Bulking, tonicity, and formulation-support excipient	May affect osmolality, sprayability, and crystallization
Dibasic sodium phosphate	Buffering agent	Controls pH and supports fentanyl stability
Hydrochloric acid and sodium hydroxide	pH adjustment	Affect stability, tolerability, and preservative performance
Purified water	Vehicle	Controls concentration, viscosity, and microbial risk

The FDA label identifies pectin, mannitol, dibasic sodium phosphate, and water as inactive formulation components, with acid or base used for pH adjustment.[1] The formulation is designed as an aqueous nasal system rather than a conventional dry powder or simple saline spray.

What excipient provides the main competitive advantage?

Pectin is the central excipient in LAZANDA. Its value comes from ion-triggered gelation in the nasal environment. The formulation can remain sufficiently fluid during actuation while becoming more viscous after exposure to nasal ions.

That behavior creates four commercial advantages:

1. It can reduce anterior nasal runoff.
2. It can improve local residence time.
3. It can support reproducible delivery from a low-volume spray.
4. It can differentiate the product from standard aqueous nasal formulations.

The excipient strategy is therefore inseparable from the device strategy. A change in pectin grade, degree of esterification, particle content, hydration profile, or concentration can alter viscosity, gel strength, spray pattern, plume geometry, priming behavior, and delivered dose.

Key critical quality attributes

A development program targeting LAZANDA should control:

• Fentanyl concentration and assay.
• Delivered dose uniformity through the labeled number of sprays.
• Spray content uniformity across the bottle.
• Droplet-size distribution.
• Plume geometry and spray angle.
• Viscosity before and after actuation.
• Pectin gelation time.
• Nasal retention and runoff.
• Osmolality and pH.
• Microbial quality and preservative performance.
• Extractables and leachables from the pump and container.
• Stability after opening, priming, and storage.

Pectin is not a plug-and-play excipient. Its raw-material variability can affect product performance. A supplier change may require comparative rheology, spray characterization, stability studies, and potentially clinical bridging.

What formulation patents protect LAZANDA-type products?

LAZANDA-type protection is likely to concentrate on formulation, gelation, nasal delivery, and device combinations rather than on fentanyl itself. The relevant patent categories include:

Pectin-based nasal compositions

Claims may cover compositions containing pectin and a pharmaceutically active agent, including concentration ranges, pectin chemistry, viscosity, and gel formation after contact with nasal fluid.

Nasal delivery of potent opioids

Claims may cover fentanyl or related opioids administered intranasally through a metered device, particularly where the formulation produces a defined pharmacokinetic profile.

Formulation-device combinations

Protection may extend to the relationship between the formulation and pump. Claim elements can include spray volume, dose per actuation, priming sequence, nozzle geometry, bottle configuration, and dose-lockout mechanisms.

Methods of treatment

Method-of-use claims may address treatment of breakthrough pain in opioid-tolerant patients, dosing intervals, titration, and administration of specific strengths.

Manufacturing and control methods

Commercial barriers can also arise from know-how rather than issued patent claims. These include pectin hydration, deaeration, filtration, filling, pump assembly, dose calibration, and controls for fentanyl containment.

The strongest defensible position is usually a layered estate covering the active formulation, in situ gel behavior, device interface, manufacturing process, and approved clinical use. A single composition patent is more vulnerable to design-around activity.

How strong is the LAZANDA excipient patent estate?

The estate is strongest where the claims require a specific combination of pectin chemistry, nasal gelation, and metered delivery. Broad claims directed only to the use of pectin as a mucoadhesive are more exposed to prior-art and obviousness challenges.

Patent strength depends on five factors:

Factor	Strong position	Weak position
Excipient definition	Specific pectin properties linked to performance	Generic reference to pectin
Functional limitation	Measurable gelation, retention, or delivery result	Unquantified “mucoadhesive” language
Device integration	Claims require a defined pump and formulation	Separate, easily substituted components
Clinical use	Narrow, approved opioid-tolerant population	Broad pain-treatment language
Manufacturing	Process parameters tied to product quality	Routine mixing and filling steps

A generic developer can attempt to avoid the estate by using a different mucoadhesive, changing pectin concentration, using a dry-powder formulation, modifying spray volume, or developing a non-gelling formulation with comparable pharmacokinetics.

What regulatory pathway is available for a LAZANDA competitor?

A conventional generic would generally pursue an ANDA under section 505(j) if the reference-product framework and FDA requirements permit it. A 505(b)(2) application may be more practical where the proposed product differs in formulation, device, strength, delivery technology, or clinical use.

ANDA strategy

An ANDA applicant would need to address:

• Same active ingredient.
• Same dosage form and route.
• Pharmaceutical equivalence.
• Bioequivalence.
• Device and dose-delivery comparability.
• Labeling requirements.
• Any listed patents and exclusivity.

For a nasal spray, systemic pharmacokinetic equivalence alone may not resolve all product-performance issues. The FDA can examine spray characteristics, dose uniformity, device performance, and local product behavior.

505(b)(2) strategy

A 505(b)(2) product could seek differentiation through:

• A new mucoadhesive.
• A different pump or container.
• A new concentration.
• A modified dose range.
• An alternative opioid-tolerant indication.
• A reduced-abuse or tamper-resistant presentation.
• Improved storage or usability.

The tradeoff is greater clinical and regulatory burden. A 505(b)(2) applicant may obtain its own three-year exclusivity for certain new clinical investigations, but that protection would not necessarily block all ANDA activity against the reference product.

When does LAZANDA lose exclusivity and what is the generic-entry risk?

LAZANDA’s market protection must be separated into FDA exclusivity, Orange Book patents, and non-patent commercial barriers.

FDA exclusivity

LAZANDA was approved in 2011. Any original five-year new chemical entity exclusivity has expired. Orphan-drug exclusivity does not appear to be the principal commercial protection for the product. Current entry risk therefore depends mainly on patents, regulatory requirements, manufacturing capability, and market demand.

Orange Book patents

Orange Book-listed patents can create a Paragraph IV litigation pathway. An ANDA applicant may certify that listed patents are invalid, unenforceable, or not infringed. A timely patent-holder action can trigger a 30-month stay of approval under the Hatch-Waxman framework, subject to statutory exceptions and court developments.[2]

For LAZANDA, the practical patent review should focus on:

• Listed formulation patents.
• Nasal delivery patents.
• Device patents.
• Method-of-use patents.
• Patent expiration and pediatric adjustments.
• Whether each claim covers the proposed generic formulation.
• Whether the reference product remains commercially active in the relevant market.

Paragraph IV risk

A Paragraph IV challenge would likely center on:

• Obviousness of combining fentanyl with pectin.
• Anticipation by earlier mucoadhesive nasal systems.
• Lack of written description for broad pectin claims.
• Noninfringement through a different pectin grade or alternative polymer.
• Noninfringement through a different device architecture.
• Lack of infringement of method-of-use claims where labeling is carved out.

The most credible generic launch scenarios are:

1. A product that waits for relevant patent expiry.
2. A Paragraph IV product with a non-pectin formulation.
3. A carved-label product avoiding protected breakthrough-pain use.
4. A 505(b)(2) product with a distinct delivery system.

What manufacturing and IP barriers affect commercial entry?

Fentanyl creates unusually high manufacturing and compliance requirements. The active ingredient is potent at microgram dose levels, making containment, cleaning validation, line clearance, and cross-contamination controls central to commercial feasibility.

Manufacturing barriers

A competitor must establish:

• Secure handling of controlled substances.
• Accurate low-dose filling.
• Pump calibration and dose reproducibility.
• Container-closure integrity.
• Robust priming and re-priming performance.
• Stability after partial use.
• Batch-to-batch control of pectin.
• Validated cleaning for potent-opioid residues.
• Compliance with DEA and FDA requirements.

The product must also perform consistently when patients administer it under real-world conditions. A nasal pump that delivers the correct dose in laboratory testing but varies after storage, temperature cycling, or incomplete priming creates a significant regulatory risk.

IP barriers

The commercial IP position can include patents, trade secrets, supplier agreements, device tooling, analytical methods, and regulatory know-how. Pectin sourcing can become a practical barrier if the sponsor has qualified a narrow grade or supplier and competitors cannot rapidly reproduce the same functional material.

What commercial opportunities exist for LAZANDA excipient technology?

Generic LAZANDA

The clearest opportunity is a lower-cost generic nasal fentanyl product. Success depends on achieving pharmaceutical equivalence and demonstrating comparable delivery without infringing surviving claims.

A non-pectin product using carbomer, chitosan, cellulose derivatives, alginate, or another mucoadhesive could reduce formulation-patent exposure. Each alternative would create new tolerability, viscosity, nasal-clearance, and device-compatibility questions.

505(b)(2) nasal opioid product

A sponsor could develop a differentiated product with:

• A smaller spray volume.
• A faster onset.
• Lower runoff.
• Improved dose-lockout.
• Simplified titration.
• An alternative concentration.
• A device that limits accidental repeat dosing.

The regulatory value would come from a clinically meaningful product difference, not from changing the excipient alone.

Platform licensing

The pectin-based delivery technology may have licensing value for other intranasal drugs where retention and rapid absorption matter. Potential targets include rescue medicines, migraine therapies, sedatives, hormones, and selected central-nervous-system products.

Licensing economics would depend on whether the platform owner grants access to:

• Formulation patents.
• Pectin specifications.
• Device designs.
• Analytical methods.
• Manufacturing process knowledge.
• Regulatory precedent and development support.

Reformulation and line extensions

Potential line extensions include:

• New bottle sizes.
• Improved priming systems.
• Child-resistant packaging.
• Unit-dose presentations.
• Lower-volume actuation.
• Storage-stable presentations.
• Formulations with improved taste or reduced throat deposition.

Each change must be assessed against the risk of creating a new combination product, new clinical requirement, or new device qualification burden.

How does LAZANDA compare with other intranasal fentanyl products?

Attribute	LAZANDA	Conventional aqueous nasal spray	Dry-powder nasal product
Core delivery mechanism	Pectin-based in situ gel	Liquid deposition without substantial gelation	Powder dispersion and dissolution
Main excipient issue	Pectin function and variability	Osmolality, pH, viscosity	Particle engineering and moisture control
Device dependence	High	High	High
Main design-around route	Alternative polymer or device	Modified formulation or dose	Different powder and device platform
Generic complexity	High	Moderate to high	High
Nasal retention	Intended to be improved	More vulnerable to runoff	Can be high but depends on powder properties
Manufacturing risk	Potent liquid filling and pectin control	Potent liquid filling	Potent powder handling and content uniformity

LAZANDA’s principal differentiation is the combination of liquid nasal dosing and mucoadhesive gelation. A competitor that abandons that combination may reduce patent exposure but could lose the performance characteristics that support the product’s clinical profile.

What is the likely revenue exposure and competitive outlook?

LAZANDA addresses a narrow market because it is limited to opioid-tolerant adults with breakthrough cancer pain. The market is also constrained by opioid-prescribing controls, competing fentanyl products, payer management, and prescriber concern about misuse and accidental exposure.

Revenue depends on:

• Continued specialist prescribing.
• Product availability.
• Reimbursement.
• Controlled-substance compliance.
• Differentiation from generic oral transmucosal fentanyl.
• Ability to maintain supply.
• Patent and litigation outcomes.

The opportunity is more attractive as a platform or licensing asset than as a broad-volume excipient business. Pectin-based intranasal delivery could support multiple products, but the highest-value programs are likely to require strong device integration and a clear clinical benefit.

What biosimilar risk applies to LAZANDA?

Biosimilar risk is not relevant because fentanyl citrate is a small-molecule active ingredient, not a biologic. The relevant competitive risk is generic substitution under an ANDA or differentiated entry under a 505(b)(2) application.

Key Takeaways

• Pectin is the core excipient differentiator in LAZANDA.
• The commercial product depends on coordinated control of excipient grade, spray device, gelation, and dose uniformity.
• Generic entry is technically feasible but requires more than matching fentanyl concentration.
• A non-pectin formulation may reduce patent risk but can create new performance and regulatory problems.
• The strongest IP position combines formulation, device, method-of-use, and manufacturing claims.
• FDA exclusivity is no longer the primary barrier; patent scope, controlled-substance compliance, and manufacturing capability are more important.
• The most attractive business opportunities are generic LAZANDA, 505(b)(2) reformulation, device improvement, and licensing of pectin-based intranasal delivery technology.
• Biosimilar competition does not apply. Generic and 505(b)(2) competition does.

FAQs

Can pectin be replaced in a LAZANDA generic?

Yes. A developer could use another mucoadhesive or a conventional aqueous formulation, but it would need to establish equivalent delivery performance, tolerability, stability, and device compatibility.

Is mannitol essential to LAZANDA?

Mannitol is an inactive formulation component, not the principal delivery technology. Its replacement could affect tonicity, viscosity, crystallization, and spray performance and would require formulation and regulatory evaluation.

Does a generic LAZANDA need to use the same nasal pump?

Not necessarily. A different pump may be used if the product satisfies applicable pharmaceutical-equivalence, bioequivalence, dose-delivery, device-performance, labeling, and patent requirements.

Can LAZANDA technology be used for non-opioid drugs?

Potentially. A pectin-based in situ gel platform could be evaluated for other intranasal medicines, but each active ingredient would require independent compatibility, pharmacokinetic, safety, and regulatory development.

Is a pectin-based formulation automatically patent protected?

No. Patent protection depends on the specific claims, patent status, jurisdiction, formulation parameters, device configuration, and proposed product. The presence of pectin alone does not establish infringement.

References

1. U.S. Food and Drug Administration. (2011). Lazanda (fentanyl citrate) nasal spray prescribing information. FDA.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. U.S. Food and Drug Administration. (2020). Transmucosal immediate-release fentanyl products risk evaluation and mitigation strategy. FDA.
4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417.
5. U.S. Food and Drug Administration. (2024). Approved drug product and patent listing requirements under the Hatch-Waxman Act. FDA.